Mabpharm's strong revenue growth may be causing investors to...

Mabpharm's strong revenue growth may be causing investors to overvalue the stock. If this growth doesn't surpass the broader industry, the stock could be overpriced. The high P/S ratio may not be sustainable without significant medium-term trend improvements.